Mainz Biomed BV
NASDAQ:MYNZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mainz Biomed BV
NASDAQ:MYNZ
|
DE |
|
FinVolution Group
NYSE:FINV
|
CN |
|
A
|
Accor SA
OTC:ACCYY
|
FR |
|
Q
|
Qualitas Ltd
ASX:QAL
|
AU |
|
Heubach Colorants India Ltd
NSE:HEUBACHIND
|
IN |
|
Netmedia Group
PAR:ALNMG
|
FR |
|
Thejo Engineering Ltd
NSE:THEJO
|
IN |
|
P
|
Proroute Marumitsu Co Ltd
TSE:8256
|
JP |
|
1000mercis SA
PAR:ALMIL
|
FR |
|
Renaissance Global Ltd
NSE:RGL
|
IN |
|
Indraprastha Gas Ltd
NSE:IGL
|
IN |
|
Horizon Bancorp Inc
NASDAQ:HBNC
|
US |
|
Motilal Oswal Financial Services Ltd
NSE:MOTILALOFS
|
IN |
|
H
|
Hiro Metaverse Acquisitions I SA
LSE:HMA1
|
LU |
|
Wyndham Hotels & Resorts Inc
NYSE:WH
|
US |
|
Nankai Plywood Co Ltd
TSE:7887
|
JP |
|
C
|
Cogna Educacao SA
OTC:COGNY
|
BR |
|
Arcos Dorados Holdings Inc
NYSE:ARCO
|
UY |
|
Y
|
Yatharth Hospital & Trauma Care Services Ltd
NSE:YATHARTH
|
IN |
|
O
|
Ondo InsurTech PLC
LSE:ONDO
|
UK |
|
R
|
Raw Edge Industrial Solutions Ltd
BSE:541634
|
IN |
|
Avalonbay Communities Inc
NYSE:AVB
|
US |
|
Companhia de Saneamento Basico do Estado de Sao Paulo SABESP
BOVESPA:SBSP3
|
BR |
|
P
|
Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS
IST:PKART.E
|
TR |
Mainz Biomed BV
Mainz Biomed BV operates as a biotechnology company. The company is headquartered in Mainz, Hessen. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Mainz Biomed BV operates as a biotechnology company. The company is headquartered in Mainz, Hessen. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
